IGF-1 Results Timeline: What Studies Measured, and When

Questions about "how long IGF-1 takes" usually assume a literature that tracks an administered compound at week 4, week 8 and week 12. The published record collected here looks different. Insulin-like growth factor 1 most often appears in trials as an outcome that was measured (a circulating biomarker moved by exercise, diet or a drug), or as a receptor that was targeted (antibody programmes in thyroid eye disease), rather than as an intervention given to volunteers on a schedule. That distinction shapes every timeline statement below.

This page is for educational purposes only and is not medical advice; consult a licensed physician about anything relating to your own health. Nothing here describes a protocol, a dose schedule or an expected personal outcome — only what the study designs measured and over what intervals.

How the Timeline Question Gets Answered in the Literature

Three separate timescales show up across the verified papers, and they are not interchangeable:

• Pharmacology timescales (hours to weeks). Studies that dosed a drug and watched hormone concentrations respond. Researchers reported that paltusotine, described as a novel oral once-daily nonpeptide SST2 receptor agonist, suppressed GH and IGF-1 in healthy volunteers (PMID 35000098).
• Intervention timescales (weeks to months). Trials in which exercise, diet, a supplement or a peptide analogue ran for a defined period, with body composition, strength, cognition or cardiometabolic endpoints measured afterwards.
• Preclinical release timescales. Bench and animal work where the delivery system itself defines the timeline, as in sequential IGF-1 and BMP-6 releasing chitosan/alginate/PLGA hybrid scaffolds built for periodontal regeneration (PMID 28601648).

Reading a biomarker timeline as if it predicted a personal outcome timeline is the most common error. A study that reported IGF-1 suppression in healthy volunteers (PMID 35000098) says something about receptor pharmacology, not about what any individual would experience.

Short Windows: Days to About Five Weeks

The shortest explicitly time-stamped human window in this citation set comes from a secondary analysis of a randomized placebo-controlled crossover study, which examined the effects of liraglutide treatment for 35 days on total and regional fat free, lean and bone mass, and on the myostatin–activin–follistatin–IGF-1 axes (PMID 41571048). The design point worth noting is that 35 days was long enough for the investigators to assay composition and axis markers together — the IGF-1 axis was treated as a short-horizon readout, not a slow one.

Acute physiology sits at an even shorter scale. A non-randomized clinical trial examined dementia risk and the dynamic response to exercise (PMID 35802628), where "dynamic response" refers to change measured around an exercise stimulus rather than after months of training. Studies of this type capture what moves within a session or a short block, which is a different question from what a sustained programme changes.

In the pharmacology literature, healthy-volunteer work on a once-daily SST2 receptor agonist reported suppression of both GH and IGF-1 (PMID 35000098). Because IGF-1 is largely hepatic and GH-driven, drug studies in this class use it as a downstream marker; the relevant timeline there is how quickly a hormone axis follows dosing, not how a tissue remodels.

Intermediate Windows: Multi-Week Interventions

Several trials in this set ran interventions long enough to measure structural or functional change, with IGF-1-adjacent biology in the background.

A randomized controlled trial tested aerobic and resistance exercise against usual care and measured metabolic syndrome, sarcopenic obesity and circulating biomarkers in overweight or obese survivors of breast cancer (PMID 29356607). The instructive part for timeline purposes is the endpoint architecture: body-composition and biomarker panels were assessed after a supervised intervention period rather than sampled weekly.

A randomized, double-blind, placebo-controlled trial of bioconversion-based postbiotics reported enhanced muscle strength and modulated gut microbiota in healthy individuals (PMID 41470885). Strength endpoints of this kind are conventionally measured at a defined end-of-intervention visit, which again means the published "result" is a single comparison point, not a curve.

Diet studies stretch the window further. A randomized clinical trial compared fasting mimicking diet cycles with a Mediterranean diet for cardiometabolic risk in overweight and obese hypertensive subjects (PMID 40604264). The word cycles matters: the exposure was intermittent and repeated, so any biomarker trajectory reflects cycling rather than continuous exposure. Nutritional work on longer horizons appears in a systematic review of diet and acne (PMID 35373155), where dietary-exposure evidence is typically observational and spans months to years — a scale at which individual weeks are meaningless.

Surgical rehabilitation supplies another kind of clock. A study of prehabilitation before anterior cruciate ligament reconstruction assessed whether pre-surgical training changed post-operative outcome (PMID 23845398), so the measurement timeline was anchored to an operation date rather than to a fixed number of weeks of exposure.

Longer Windows: IGF-1 Pathway Drugs and Clinical Endpoints

Where IGF-1 biology is the therapeutic target rather than the measurement, trial durations follow clinical endpoints. A phase 3, randomized, double-masked, placebo-controlled study named THRIVE evaluated veligrotug for active thyroid eye disease (PMID 42223386), a condition whose pharmacology has centred on the IGF-1 receptor pathway. Background on that disease area, including how orbitopathy activity and severity are graded before treatment decisions, is summarised in a German-language review of Graves' orbitopathy (PMID 34644795). In these programmes, the endpoint is an eye-disease measure assessed at a protocol-defined visit, and the underlying tissue changes are expected over months.

Growth-axis pharmacology with a cognitive endpoint appears in a trial of tesamorelin, a growth hormone-releasing hormone analogue, which examined neurocognitive impairment in persons with HIV and abdominal obesity (PMID 39813152). Cognitive endpoints are slow-moving by nature, which is why studies of this type run far longer than the hormone-suppression studies described above.

Preclinical Timelines, Clearly Labelled

Human data on administered IGF-1 with staged week-by-week outcome measurement is thin in this citation set — that gap should be stated plainly rather than filled with inference. What exists in the preclinical column is instructive about engineered timing: researchers built sequential IGF-1 and BMP-6 releasing chitosan/alginate/PLGA hybrid scaffolds for periodontal regeneration (PMID 28601648), where the growth factors were deliberately released in sequence rather than together. The premise of that work is that the order and spacing of exposure influence tissue outcomes — a laboratory construct, not a human dosing finding, and not transferable to people.

Timeline Summary Table

Why "Week 4, Week 8, Week 12" Rarely Fits IGF-1

Four structural reasons explain the mismatch between the question and the literature.

1. IGF-1 is often the dependent variable. In the liraglutide crossover analysis, the IGF-1 axis was an outcome assayed alongside body composition over 35 days (PMID 41571048), not a treatment being timed.
2. Endpoint biology sets the clock. Hormone suppression can be read quickly (PMID 35000098), while eye-disease activity (PMID 42223386) and neurocognitive measures (PMID 39813152) require far longer observation.
3. Exposure patterns differ. Continuous daily dosing, repeated diet cycles (PMID 40604264) and sequential scaffold release (PMID 28601648) produce non-comparable trajectories.
4. Populations differ. Healthy volunteers (PMID 41470885) and clinical populations such as breast cancer survivors (PMID 29356607) start from different baselines, so identical durations do not imply identical findings.

Adverse Events Across These Timelines: What Studies Report

The verified papers here were built around efficacy and biomarker endpoints, and their titles and abstract-level scope do not provide timepoint-by-timepoint adverse-event breakdowns for administered IGF-1. What can be said is procedural: randomized, double-masked, placebo-controlled phase 3 designs such as the THRIVE study of veligrotug in active thyroid eye disease include structured safety collection alongside the efficacy endpoint (PMID 42223386), as do placebo-controlled crossover analyses of the kind used to study liraglutide over 35 days (PMID 41571048) and controlled trials in clinical populations such as persons with HIV and abdominal obesity (PMID 39813152). Anyone summarising tolerability from these sources should read each full report rather than infer it from a timeline.

What the Literature Does Not Establish

None of the studies above supports a statement about when an individual would notice anything, and none of them describes a consumer use pattern. The clinical work summarises populations under controlled conditions — healthy volunteers in hormone pharmacology (PMID 35000098), patients in disease-specific programmes (PMID 42223386) — and the regeneration work sits entirely in preclinical biomaterials (PMID 28601648). Where human timeline data on administered IGF-1 is thin, the honest description is that it is thin.

References

• Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers (Pituitary, 2022)
• Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study (Diabetes Research and Clinical Practice, 2026)
• Dementia risk and dynamic response to exercise: A non-randomized clinical trial (PLoS One, 2022)
• Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial (Journal of Clinical Oncology, 2018)
• Bioconversion-Based Postbiotics Enhance Muscle Strength and Modulate Gut Microbiota in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Trial (Nutrients, 2025)
• Fasting mimicking diet cycles versus a Mediterranean diet and cardiometabolic risk in overweight and obese hypertensive subjects: a randomized clinical trial (npj Metabolic Health and Disease, 2023)
• Effect of prehabilitation on the outcome of anterior cruciate ligament reconstruction (The American Journal of Sports Medicine, 2013)
• Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity (The Journal of Infectious Diseases, 2025)
• THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease (Ophthalmology, 2026)
• [Graves' orbitopathy] (Deutsche Medizinische Wochenschrift, 2021)
• Sequential IGF-1 and BMP-6 releasing chitosan/alginate/PLGA hybrid scaffolds for periodontal regeneration (International Journal of Biological Macromolecules, 2017)
• Diet and acne: A systematic review (JAAD International, 2022)